ZYME Zymeworks Inc.
Price Chart
Executive Summary
Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net loss to $81.1 million. The company secured $250.0 million in non-dilutive financing from Royalty Pharma and is executing a $125.0 million share repurchase program, having already used $62.5 million. Key catalysts include the potential U.S. approval and 2026 launch of Ziihera in first-line HER2+ gastroesophageal cancer, which could trigger up to $440.0 million in milestone payments.
Key Financial Metrics
Actionable Insight
Traders should monitor the sBLA submission for Ziihera in first-line GEA in 1Q 2026 and potential NCCN guideline inclusion as near-term catalysts. The Royalty Pharma financing de-risks the balance sheet and extends cash runway beyond 2028, supporting continued buybacks or strategic acquisitions. Upcoming data presentations at AACR in April 2026 could provide additional R&D momentum.
Key Facts
- Total revenue for 2025 was $106.0 million, up 39% from $76.3 million in 2024
- Net loss for 2025 was $81.1 million, a 34% improvement from $122.7 million in 2024
- Entered into $250.0 million non-recourse royalty-backed note financing with Royalty Pharma
- Utilized $62.5 million of a $125.0 million share repurchase program as of March 2, 2026
- Partner Jazz expects to submit sBLA for Ziihera in first-line HER2+ GEA in 1Q 2026 with potential U.S. launch in 2H 2026
- Eligible for up to $440.0 million in milestone payments from Jazz and BeOne for Ziihera approvals in GEA across U.S., Europe, Japan, and China
- Cash, cash equivalents, and marketable securities totaled $270.6 million as of December 31, 2025
- Guided for approximately $300.0 million in adjusted gross operating expenses (non-GAAP) over 2026–2028, with 2026 expenses ~20% lower than 2025
Financial Impact
Revenue increased by $29.7 million YoY; net loss reduced by $41.6 million; $250.0 million non-dilutive financing secured; $62.5 million returned to shareholders via buybacks
Risk Factors
- Regulatory delay or rejection of Ziihera sBLA in first-line GEA
- Failure to realize anticipated milestone payments from partners
- Clinical setbacks in wholly-owned pipeline programs (ZW191, ZW251, ZW209, ZW1528)
- Execution risk around cost discipline and operating expense reductions
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247159 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
3
| $24.43 $25.40 | ▲ +3.97% | ▲ +2.35% | $23.93 (−2.05%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $28.53 $27.65 | ▼ −3.08% | ▼ −3.14% | $23.93 (−16.12%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $27.80 $28.10 | ▲ +1.08% | ▲ +0.52% | $23.93 (−13.92%) |
|
Apr 16, 2026
7w ago
|
Press Release
| $27.20 $27.43 | ▲ +0.85% | ▼ −0.14% | $23.93 (−12.02%) |
|
Apr 10, 2026
8w ago
|
3
| $26.17 $27.85 | ▲ +6.42% | ▲ +3.12% | $23.93 (−8.56%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $23.45 $24.23 | ▲ +3.33% | ▲ +4.04% | $23.93 (+2.05%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $23.31 $24.25 | ▲ +4.03% | ▲ +5.24% | $23.93 (+2.66%) |
|
Mar 2, 2026
14w ago
|
Press Release
| $23.31 $24.25 | ▲ +4.03% | ▲ +5.24% | $23.93 (+2.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access